{
    "symbol": "VALN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 15:52:05",
    "content": " The first company that will receive BLA approval might be eligible to a priority review voucher, which in turn we \u00e2\u0080\u0093 of course expect to monetize, Lyme Phase 3 enrollment well underway, the way with the next milestone expected earlier next year partnered with Pfizer. Finally, COVID-19 vaccine sales increased \u00e2\u0082\u00ac3.8 million at the end of June to \u00e2\u0082\u00ac23.9 million in September year-to-date, driven by shipments to European member states in Q3, as mentioned by Thomas earlier. And of course, we are \u00e2\u0080\u0093 as we have clearly articulated in the past, in touch with a few international markets, meaning countries in Middle East, Asia, for example, where we are trying to a, seek regulatory approval and b, potential sales of our existing COVID-19 vaccine VLA2001 in respected inventory, this all of course to maximize the value from the existing assets. Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open. Your line is open. One moment for our next question. Your line is open. Your line is open."
}